Adults With T2D Taking SGLT2is Show Significant Treatment Failure

Treatment failure was prominent among adults with type 2 diabetes (T2D) that initiated treatment of sodium-glucose cotransporter 2 inhibitors (SGLT2is), according to a study in Diabetes & Metabolic Syndrome: Clinical Research & Reviews.¹ Highlighting the need for a more optimized approach to SGLT2i treatment, researchers also uncovered a significant clinical and economic burden among this population.

“SGLT2is prevent the reabsorption of glucose into the bloodstream, thereby reducing blood glucose levels,” wrote the authors of the study. “The effects of SGLT2i on glycemic control and reductions in cardiovascular events, chronic kidney disease…